AKTX Celsus Therapeutics PLC

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the investor-focused Cantor Oncology & HemOnc Conference on September 28, 2022. President and CEO Rachelle Jacques will take part in a conference panel, Addressing Challenges in Cell Therapy and Transplant, at 9:00 a.m. Eastern time and will attend 1:1 investor meetings.

About Akari Therapeutics

Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of C5 complement activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), as well as pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit .

Investor Contact:

Mike Moyer

LifeSci Advisors

(617) 308-4306

Media Contact:

Eliza Schleifstein

Schleifstein PR   

(917) 763-8106



EN
22/09/2022

Underlying

AKTXCelsus Therapeutics PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celsus Therapeutics PLC

 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Announces Abstract Accepted for Oral Presentation a...

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at the being held November 5-9, 2025 in National Harbor, MD. Details of the oral presentation are as follows: Title: A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Check...

October 3, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its...

Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1 Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies have proven to be effective in AR-V7 driven tumors BOSTON and LONDON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced key preclinical data ...

September 24, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platf...

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering the Company’s antibody drug conjugate (ADC) platform using Akari’s spliceosome payload PH1 for treating cancer by modulating alternative s...

September 17, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Globa...

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the being held from September 8-10, 2025 in New York, NY.  In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of ...

September 5, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics to Participate in the Virtual Investor Closing Bell...

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that it will participate in the on Thursday, September 4, 2025 at 4:00 PM ET. As part of the event, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch